Avacta Group Plc (OTCMKTS:AVCTF – Get Free Report) was the target of a large increase in short interest during the month of July. As of July 15th, there was short interest totaling 51,929 shares, an increase of 64.5% from the June 30th total of 31,567 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is currently ∞ days.
Avacta Group Stock Performance
Shares of AVCTF stock opened at $0.91 on Friday. The firm has a 50 day moving average price of $0.98 and a two-hundred day moving average price of $0.92. Avacta Group has a 12-month low of $0.45 and a 12-month high of $1.23.
Avacta Group Company Profile
Avacta Group plc is a UK-based biotechnology company specializing in the discovery, development and commercialization of Affimer® biotherapeutics and diagnostic reagents. The company’s proprietary Affimer platform uses small, engineered protein scaffolds that can be tailored to bind specifically to target molecules, offering an alternative to traditional antibodies. Avacta operates two core divisions: Avacta Therapeutics, which focuses on novel treatments in oncology and immune-related diseases, and Avacta Analytical, which develops reagents and point-of-care diagnostic tests.
In its diagnostics business, Avacta has applied the Affimer technology to lateral flow assays, most notably for rapid detection of viral pathogens such as SARS-CoV-2.
Featured Stories
- Five stocks we like better than Avacta Group
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.
